ライフサイエンスコーパス: tumor lesion

1 ntitative analysis by measurement of SUVs in tumor lesions.

2 king of tumor antigen-specific CTLs into CNS tumor lesions.

3 at the CNT1 protein was indeed absent in the tumor lesions.

4 KSF did not improve visualization of tumor lesions.

5 growth associated with the establishment of tumor lesions.

6 ges were collected to determine targeting of tumor lesions.

7 the uptake and retention of radioactivity in tumor lesions.

8 was measured in healthy tissues, organs, and tumor lesions.

9 tected 73% and (68)Ga-FAPI PET/CT 94% of all tumor lesions.

10 r when ER heterogeneity is suspected between tumor lesions.

11 performed by 2 experienced readers to count tumor lesions.

12 evaluation was performed for main organs and tumor lesions.

13 injection: 4.3-25.9) over time was found in tumor lesions.

14 ents with high-grade tumors 91% had positive tumor lesions.

15 differences were found for normal organs or tumor lesions.

16 higher absorbed radiation dose to individual tumor lesions.

17 image biomarkers in both healthy tissues and tumor lesions.

18 )Ga-PSMA-11 accumulation in normal organs or tumor lesions.

19 ated rapid tissue uptake and localization at tumor lesions.

20 ng enhanced antitumor activity against brain tumor lesions.

21 to measure the SUV(mean) or SUV(max) of the tumor lesions.

22 ric maps to visualize the characteristics of tumor lesions.

23 of (18)F-FDG-positive, PSMA ligand-negative tumor lesions.

24 hroughout the brain, and accumulate in brain tumor lesions.

25 gy analyzed the PET/CT measuring SUV(max) in tumor lesions.

26 man pancreatic cancer primary and metastatic tumor lesions.

27 and immunosuppressive potential of MDSCs in tumor lesions.

28 distribution in normal tissues and uptake in tumor lesions.

29 fically reflect monocyte activity in primary tumor lesions.

30 mixture of NiSO4 and (68)Ga to simulate hot tumor lesions.

31 a 10-fold increase in the number and size of tumor lesions.

32 ia selective depletion of T reg cells within tumor lesions.

33 ng and providing information on ER status of tumor lesions.

34 multiple immune suppressions in established tumor lesions.

35 ced the production of CXCL10 and CCL5 in all tumor lesions.

36 ppressor cells and regulatory T cells in the tumor lesions.

37 pression of programmed death-ligand 1 in the tumor lesions.

38 In the remaining patients, 19% of tumor lesions 1 cm or greater known by CT were visualize

39 +/- 0.8 and 9.5 +/- 0.7, respectively), and tumor lesions (16.8 +/- 1.7 and 10.1 +/- 1.1, respective

40 as (12.2 0.8 and 9.5 0.7, respectively), and tumor lesions (16.8 1.7 and 10.1 1.1, respectively) and

41 than for [(177)Lu]Lu-PSMA-I&T in soft tissue tumor lesions (4.19 vs. 2.94 Gy/GBq; P = 0.26).

42 populations within the same tumor or between tumor lesions, a phenomenon termed tumor heterogeneity.

43 f interest was placed in the parenchyma; for tumor lesions, a threshold-segmented volume of interest

44 8082A uptake in normal lymphoid tissues, and tumor lesions across the body varying within and between

45 V(mean), and total SUV (SUV(total)) from all tumor lesions, active lymph nodes, spleen, vertebral bon

46 significant changes in SUV(max) were seen in tumor lesions after treatment initiation.

47 Tumor lesion and healthy-tissue uptake was quantified an

48 tributes to differential drug responses in a tumor lesion and potential therapeutic resistance.

49 SMA-617 PET/CT detected 74.3% (26/35) of all tumor lesions and (68)Ga-RM2 PET/CT detected 78.1% (25/3

50 ; 76 [79%] female), 72 (75%) had more than 3 tumor lesions and 65 (68%) had received at least 1 previ

51 Without Id2, Rb(+/-) mice have fewer early tumor lesions and a markedly decreased proliferation rat

52 B16 melanoma model to profile chemokines in tumor lesions and assess their impact on gammadelta TIL

53 icancer prodrugs for the eradication of deep tumor lesions and broadens the biomedical uses of Pt coo

54 Tracer uptake was quantified by SUV(max) for tumor lesions and by SUV(mean) for normal organs.

55 exploits the natural anti-Gal Ab to destroy tumor lesions and convert them into an endogenous vaccin

56 rostate tissue and malignant, intraprostatic tumor lesions and correlates results with several clinic

57 erm blockade, increases the frequency of pre-tumor lesions and creates a tumor-permissive microenviro

58 ay be the most beneficial in detecting small tumor lesions and disease staging.

59 Furthermore, the SUVs in tumor lesions and healthy tissues agreed well (within 95

60 ns were also used for measurements of SUV in tumor lesions and healthy tissues for comparison between

61 tor is induced in multiple cell types within tumor lesions and its increased expression is associated

62 nostimulatory mAbs to act both on irradiated tumor lesions and on distant, nonirradiated tumor sites.

63 Absorbed dose to tumor lesions and organs was calculated using OLINDA sof

64 licular helper T cells (Tfh) in unirradiated tumor lesions and patient's blood, as well as of circula

65 adjacent mucosa were similar to those in the tumor lesions and significantly higher than those in the

66 ed oHSV alone, effectively tracks metastatic tumor lesions and significantly prolongs the survival of

67 one may exacerbate immune suppression in the tumor lesions and that methods to improve the tumor micr

68 The favorable immunologic changes in tumor lesions and the improvement of antitumor effects f

69 ble approach to increase the antigenicity of tumor lesions and thereby enhance the effectiveness of i

70 to an enhanced radioactivity uptake into the tumor lesions and, thus, to a potentially improved thera

71 n A neutralizing antibody were evaluated for tumors, lesions and metastases quantified by immunohisto

72 C PET/CT was true-positive in 5 patients (10 tumor lesions) and was false-positive in 1 patient.

73 ressions are mutually exclusive in migratory tumor lesions, and GBM patients with MSI1(high)/TNS3(low

74 Within early stage tumor lesions, and in an in vivo and endogenous tumor mi

75 In total, 76% of patients had positive tumor lesions, and of the patients with high-grade tumor

76 Because tumor lesions are a complex mixture of cell types, we hy

77 and Pten+/-Tsc2+/- mice, whereas TSC-related tumor lesions are invariably associated with Tsc2 loss o

78 o favorable effects on distant nonirradiated tumor lesions as observed in transplanted MC38 (colorect

79 s indicated a uniform presence of KSHV in KS tumor lesions as revealed by polymerase chain reaction a

80 s to target PSMA and visualize PSMA-positive tumor lesions as shown in preclinical evaluation by smal

81 radioligand accumulation was seen in primary tumor lesions as well as in metastases.

82 (99m)Tc-FAPI-34 accumulated in the tumor lesions, as also shown on PET/CT imaging using (68

83 onsidering a cohort of heterogeneously-sized tumor lesions, as would be clinically expected.

84 marrow, liver, and lacrimal glands) and for tumor lesions (bone and nonbone lesions) were extracted

85 e uptake of (188)Re-liposome was detected in tumor lesions but not in surrounding normal lung tissues

86 was not only able to detect tissue types and tumor lesions, but also the tumor type and mutation stat

87 alone but not ultrasound identified 2 of 10 tumor lesions, but in both patients (68)Ga-DOTATOC-PET/C

88 ination resulted in profound infiltration of tumor lesions by CD8(+) (but not CD4(+)) T cells, in a c

89 8)Ga-NOTA-AE105, and SUVs were obtained from tumor lesions by manually drawing volumes of interest in

90 nd biodistribution within healthy organs and tumor lesions by using (68)Ga-PSMA-11 PET imaging.

91 ER expression in tumor lesions can be visualized by (18)F-fluoroestradiol

92 e, potentially compromising the detection of tumor lesions close to the prostate.

93 cevumeran-induced T cells were found within tumor lesions constituting up to 7.2% of tumor-infiltrat

94 and scored (using a Likert scale of 1-5) on tumor lesion demarcation, overall image quality, and ima

95 h Vision were scored significantly higher on tumor lesion demarcation, overall image quality, and ima

96 CART resists exhaustion and apoptosis inside tumor lesions, demonstrating a greater therapeutic poten

97 es in SUV(max) were found in normal liver or tumor lesions dependent on the interval between last dos

98 PET/CT using (68)Ga-DOTA-MGS5 showed a high tumor lesion detection rate in patients with MTC, with l

99 dose with [(177)Lu]Lu-PSMA-I&T and a higher tumor lesion dose with [(177)Lu]Lu-PSMA-617.

100 diation absorbed doses to normal tissues and tumor lesions during radioimmunotherapy with (177)Lu-cG2

101 nteraction for the treatment of KS and other tumor lesions, exhibiting hyperactive mTOR pathway funct

102 ion of PET imaging and the intense uptake in tumor lesions, facilitating detection.

103 arboplatin had a 30% reduction in her target tumor lesions following pembrolizumab treatment with a P

104 )-5-methylcytosine (l-(18)F-FMAC) to profile tumor lesions for both dCK and CDA enzymatic activities;

105 Analyses of tumor lesions from 38 Ugandan KS patients indicated a un

106 -SD) peak standardized uptake value in index tumor lesions from 6.4 +/- 3.9 to 9.1 +/- 5.6 (P = 0.037

107 e of BRAF/NRAS/p16CDKN2A mutations in paired tumor lesions from patients with melanoma may be useful

108 erapy to calculate the directional change in tumor lesion glycolysis (Delta-TLG).

109 Metabolic tumor activity, defined as tumor lesion glycolysis (TLG*) on (18)F-FDG PET, was mea

110 ntly, total metabolic tumor volume (MTV) and tumor lesion glycolysis have emerged as promising and ro

111 vacizumab PET scans visualized 125 evaluable tumor lesions in 22 patients, with a median SUV(max) (ma

112 by obtaining fine-needle aspirations from 52 tumor lesions in 30 patients with melanoma before and so

113 onstrated sufficient (90)Y-FAPI-46 uptake in tumor lesions in 7 of 9 patients (78%).

114 man herpesvirus type 8 have been found in KS tumor lesions in high frequency.

115 d been also shown that ABT-510 could regress tumor lesions in pet dogs or cause unexpected stabilizat

116 tically reprogram and expand host T cells at tumor lesions in situ.

117 Seven patients (25%) showed new tumor lesions in the FRL after PVE, of whom 3 patients (

118 h biopsies further confirmed the presence of tumor lesions in the mouse lungs.

119 ted to different biologic characteristics of tumor lesions in the same patient-differences that may a

120 between tumor tissue and mucus and to detect tumor lesions in the small intestine regions, which caus

121 ild-type mice were competent to migrate into tumor lesions in vivo.

122 nes in vitro as well as in Kras(G12D)-driven tumor lesions in vivo.

123 the colon of mutant mice spontaneously, and tumor lesions, including invasive carcinoma, arose in th

124 ial steps, including the growth of a primary tumor lesion, intravasation of circulating tumor cells (

125 Tumor lesion is characterized as chronic indolent inflam

126 ly, elevated expression of IL-9R and Arg1 in tumor lesions is associated with poor prognosis in lung

127 s cohort, the average absorbed doses in bone tumor lesions, kidneys, red bone marrow, and bone surfac

128 Targeting of all known tumor lesions < 0.5 cm [corrected] in diameter was possi

129 ad minimal residual or small-volume disease (tumor lesions < or = 3 cm in diameter).

130 the kidneys, liver, spleen, bone marrow, and tumor lesions (<=4 per patient) was based on the activit

131 ses in the regulation of inflammation within tumor lesions, making the targeting of matrix metallopro

132 Tracer uptake was visualized in 47.2% of 72 tumor lesions measuring BetaChiRho20 mm in the long-axis

133 Tracer uptake was visualized in 47.2% of 72 tumor lesions measuring BXP20 mm in the long-axis diamet

134 1.1; modified RECIST; and PERCIST using both tumor lesion metabolic activity in a 1 cm(3) spheric reg

135 e most prominent (18)F-FDG uptake (reference tumor lesion): mG1, tumor-to-liver ratio of maximum stan

136 s depicted by S100A9 activity in the primary tumor lesion mirrored the tumor's metastatic behavior.

137 In the presence of tumor lesions, monocytic-myeloid-derived suppressor cell

138 ients (68)Ga-DOTATOC-PET/CT revealed further tumor lesions not detected on CT alone.

139 Expression of DKK1 and CKAP4 was frequent in tumor lesions of human pancreatic and lung cancers, and

140 Pathologic analysis revealed a total of 16 tumor lesions, of which PET/CT showed 14, resulting in a

141 spectrum of cancer cells present in a given tumor lesion or patient.

142 ture disease heterogeneity within individual tumor lesions or among several lesions within the same p

143 as the ratio of mean pretherapeutic doses to tumor lesions over relevant organs at risk.

144 The reactive stroma surrounding tumor lesions performs critical roles ranging from suppo

145 slational response and cell proliferation in tumor lesions, pointing to mTOR inhibition as a therapeu

146 Malignant tumor lesions (predominantly squamous cell carcinoma in

147 that tumor cells in different locations of a tumor lesion present heterogenous sensitivity or resista

148 nt had significant reduction (81%) in target tumor lesions prior to treatment discontinuation at cycl

149 fusion protein or agonist mAb into EphA2(+) tumor lesions promotes EphA2 degradation in situ, this s

150 Tumor lesions received mean absorbed doses of (177)Lu-rh

151 Tumor lesions received mean absorbed doses of (177)Lu-rh

152 Measured tumor lesions received up to 2.28 Gy/GBq (median, 1.28 G

153 lasting 7 months before multiple plaque and tumor lesions recurred, along with the development of in

154 Autoradiography of tumor lesions revealed heterogeneous GRPr expression and

155 esized that focal boosting of intraprostatic tumor lesion(s) in addition to standard external beam ra

156 Of 53 representative tumor lesions selected at 3 h after injection, 47 lesion

157 Tumor lesions showed maximum uptake at 20-64 h after inj

158 These findings suggest that comparing tumor lesion sizes and categorizing treatment response a

159 cers, such as highly vascular and red/purple tumor lesions, spindle-shaped cells, an insignificant ro

160 The observed targeting of tumor lesions suggests this may be informative for CD8+

161 Tumor lesion SUV(mean) and SUV(max) also decreased by 38

162 , scans at 3 h after injection detected more tumor lesions than at 1 h after injection.

163 mice causes multiple hyperproliferative and tumor lesions that strikingly resemble Cowden's disease.

164 technologies and tools for direct access to tumor lesions, the clinical applicability of locoregiona

165 tion in vivo to detect orthotopic pancreatic tumor lesions through active targeting of the EGF recept

166 sive methods that can detect DCK activity in tumor lesions throughout the body could circumvent these

167 1/Tc1-like proinflammatory milieu within the tumor lesion to boost the effector phase of immune respo

168 tration, had sufficient isotope retention in tumor lesions to make external imaging possible.

169 urvival advantage in situ when injected into tumor lesions, to be found in approximation with regions

170 8)Ga-NODAGA-E[c(RGDyK)](2) PET/CT would show tumor lesion uptake and that higher tumor lesion uptake

171 Conclusion: Tumor lesion uptake of (68)Ga-NODAGA-E[c(RGDyK)](2) was

172 ed well with changes in RECIST sum and total tumor lesion uptake on serial (68)Ga-DOTATATE PET-CT sca

173 uld show tumor lesion uptake and that higher tumor lesion uptake was associated with a poorer prognos

174 ained by semiautomatic segmentation of total tumor lesions using qPSMA software.

175 s possible in nine patients and at least one tumor lesion was evident in all patients.

176 The average retention in tumor lesions was 0.02% injected activity per gram at 6

177 SUVmax on day 4 in tumor lesions was 4.6 (range, 1.5-13.9) versus a median

178 The median SUVmax of 94 tumor lesions was 7.3 (range, 1.6-59.5).

179 The absorbed dose for tumor lesions was calculated with dosimetry software.

180 se in NK cell number in organ parenchyma and tumor lesions was correlated to an increase in the numbe

181 Results: Uptake of [(68)Ga]pentixafor in tumor lesions was demonstrated in all patients with DSRC

182 When a LSIR within tumor lesions was detected on diffusion-weighted images

183 The SUVmax of tumor lesions was determined using region-of-interest an

184 Tracer uptake in tumor lesions was heterogeneous.

185 ip between the mass and absorbed dose of the tumor lesions was observed.

186 e of several organs and of 53 representative tumor lesions was performed in 15 patients at 1 and 3 h

187 Uptake in organs and tumor lesions was quantified and compared by calculation

188 Uptake in tumor lesions was seen on imaging as early as 2 h after

189 In total, 27 tumor lesions were analyzed, with a median SUV(peak) of

190 Tumor lesions were assessed by computed tomography scan

191 Tumor lesions were assessed every 6 weeks, and patients

192 measurements of SUV(max) in normal liver and tumor lesions were compared.

193 Positive tumor lesions were defined as those with tumor-to-liver

194 xtracted and quantified, and PSMA-expressing tumor lesions were delineated to extract the PSMA-TVs.

195 Results: In total, 4,709 different tumor lesions were detected: 3,454 with (68)Ga-DOTATATE/

196 At completion of imaging, suspected tumor lesions were dissected for histopathologic confirm

197 ing the whole body, organs, bone marrow, and tumor lesions were drawn for each patient.

198 For each patient, up to 7 tumor lesions were evaluated.

199 Tumor lesions were found in the colons of most Fn14(-/-)

200 n sites of malignancy, suggesting that these tumor lesions were HER2-positive.

201 In total, 42 tumor lesions were identified at baseline, with most les

202 The SUVmax and contrast of 149 tumor lesions were measured in 69 patients with patholog

203 f 150 resected regions in 54 of 58 patients, tumor lesions were present in histopathology.

204 Tumor lesions were segmented using a 40% isocontour volu

205 The salivary glands and whole-body tumor lesions were segmented using qPSMA software.

206 Tumor lesions were segmented, and total PSMA-positive tu

207 (68)Ga-DOTATOC-avid tumor lesions were semi-automatically delineated using a

208 (68)Ga-DOTATOC-avid tumor lesions were semiautomatically delineated using a

209 Although tumor lesions were smaller in Kit(V558;T669I/+) mice tha

210 PSMA(+) tumor lesions were visualized through SPECT/CT as early

211 any tracer-related adverse events, and more tumor lesions were visualized using the tracer dose-only

212 In 4 of the 14 patients entered, no tumor lesions were visualized with (89)Zr-bevacizumab PE

213 Most tumor lesions were visualized with the tracer dose only

214 ves to identify heterogeneous uptake between tumor lesions, whereas subcentimeter intralesional heter

215 ment with LA SSA does not change SUV(max) in tumor lesions, whereas SUV(max) in normal liver is signi

216 rated increased (89)Zr-Df-IAB22M2C uptake in tumor lesions, which correlated with response.

217 n of carbonic anhydrase IX (CAIX)-expressing tumor lesions with chimeric monoclonal antibody (mAb) gi

218 All tumor lesions with GS 4 + 3 or higher were detected on P

219 sential prerequisite for robust detection of tumor lesions with low PSMA expression on PET/CT scans.

220 prevents the beam from being targeted to the tumor lesion without also irradiating the artery wall.